stoxline Quote Chart Rank Option Currency Glossary
  
PaxMedica, Inc. Common Stock (PXMD)
0.24  0.019 (8.35%)    07-23 14:50
Open: 0.2215
High: 0.24
Volume: 3,200
  
Pre. Close: 0.2215
Low: 0.2215
Market Cap: 2(M)
Technical analysis
2024-07-23 4:54:42 PM
Short term     
Mid term     
Targets 6-month :  0.32 1-year :  0.37
Resists First :  0.27 Second :  0.32
Pivot price 0.23
Supports First :  0.2 Second :  0.16
MAs MA(5) :  0.24 MA(20) :  0.22
MA(100) :  0.42 MA(250) :  2.39
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  33.4 D(3) :  35.2
RSI RSI(14): 48.7
52-week High :  12.92 Low :  0.2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PXMD ] has closed below upper band by 38.5%. Bollinger Bands are 71.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.24 - 0.24 0.24 - 0.24
Low: 0.22 - 0.22 0.22 - 0.22
Close: 0.24 - 0.24 0.24 - 0.24
Company Description

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.

Headline News

Fri, 12 Apr 2024
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - Benzinga

Wed, 22 Nov 2023
PaxMedica Announces Pricing of $7M Public Offering - Yahoo Finance

Tue, 31 Oct 2023
PaxMedica (NASDAQ: PXMD) to jump 1,700% today - purely nominal and technical - Dhaka Tribune

Tue, 31 Oct 2023
Paxmedica Inc (PXMD) Quote - Press Release - The Globe and Mail

Mon, 30 Oct 2023
PaxMedica Announces 1-for-17 Reverse Stock Split - Yahoo Finance

Thu, 27 Jul 2023
Is PaxMedica Inc. Stock a Good Buy? - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 8 (M)
Shares Float 7 (M)
Held by Insiders 0 (%)
Held by Institutions 0.7 (%)
Shares Short 638 (K)
Shares Short P.Month 552 (K)
Stock Financials
EPS 68.22
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.15
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -258.3 %
Return on Equity (ttm) -975.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -11 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 1.5
Price to Sales 0
Price to Cash Flow -0.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android